Advertisement
Screener

Summit Therapeutics Inc. (SMMT) Cash Flows From Used In Operations

2.8 / 5 stars · 68/120 Roast Me

Summit Therapeutics Inc. Cash Flows From Used In Operations

Summit Therapeutics Inc. (SMMT) reported Cash Flows From Used In Operations of -GBP 6.70 million for the 3-month period ending 2020-03-31, per its 6-K filed 2020-06-02.

Discontinued › Notes

ifrs-full:CashFlowsFromUsedInOperations · last filed 2020-06-02

  • Summit Therapeutics Inc. cash flows from used in operations for the quarter ending 2020-03-31 was -6.70M GBP.
  • Summit Therapeutics Inc. cash flows from used in operations for the quarter ending 2019-10-31 was -6.88M GBP.
  • Summit Therapeutics Inc. cash flows from used in operations for the quarter ending 2019-07-31 was -7.78M GBP.
  • Summit Therapeutics Inc. cash flows from used in operations for the quarter ending 2019-04-30 was -3.50M GBP.
Period endCash Flows From Used In Operations 3 monthCash Flows From Used In Operations 3 month as first filedCash Flows From Used In Operations 6 monthCash Flows From Used In Operations 6 month as first filedCash Flows From Used In Operations 9 monthCash Flows From Used In Operations 9 month as first filedCash Flows From Used In Operations 11 monthCash Flows From Used In Operations 12 monthCash Flows From Used In Operations 12 month as first filed
2020-03-31-6.70M GBP
6-K · filed 2020-06-02
2019-12-31-21.87M GBP
20-F · filed 2020-04-30
2019-10-31-6.88M GBP
derived: 6-K 9 month − 6-K 6 month · filed 2019-12-17
-14.65M GBP
derived: sum of 2 quarters · filed 2019-12-17
-18.16M GBP
6-K · filed 2019-12-17
2019-07-31-7.78M GBP
derived: 6-K 6 month − 6-K 3 month · filed 2019-10-11
-11.28M GBP
6-K · filed 2019-10-11
2019-04-30-3.50M GBP
6-K · filed 2019-06-12
2019-03-31-8.10M GBP
6-K · filed 2020-06-02
2019-01-31-3.99M GBP
derived: 20-F 12 month − 6-K 9 month · filed 2020-04-30
-8.51M GBP
derived: sum of 2 quarters · filed 2020-04-30
-19.34M GBP
derived: sum of 3 quarters · filed 2020-04-30
-26.30M GBP
20-F · filed 2020-04-30
-26.95M GBP
20-F · filed 2019-03-29
2018-10-31-4.52M GBP
derived: 6-K 9 month − 6-K 6 month · filed 2019-12-17
-15.35M GBP
derived: sum of 2 quarters · filed 2019-12-17
-22.31M GBP
6-K · filed 2019-12-17
-22.55M GBP
6-K · filed 2018-12-11
-31.48M GBP
derived: sum of 4 quarters · filed 2020-04-30
2018-07-31-10.83M GBP
derived: 6-K 6 month − 6-K 3 month · filed 2019-10-11
-17.79M GBP
6-K · filed 2019-10-11
-17.95M GBP
6-K · filed 2018-09-20
-26.96M GBP
derived: sum of 3 quarters · filed 2020-04-30
-37.33M GBP
derived: sum of 4 quarters · filed 2020-04-30
2018-04-30-6.96M GBP
6-K · filed 2019-06-12
-7.04M GBP
6-K · filed 2018-06-05
-16.13M GBP
derived: sum of 2 quarters · filed 2020-04-30
-26.50M GBP
derived: sum of 3 quarters · filed 2020-04-30
-16.91M GBP
derived: sum of 4 quarters · filed 2020-04-30
2018-01-31-9.17M GBP
derived: 20-F 12 month − 6-K 9 month · filed 2020-04-30
-19.54M GBP
derived: sum of 2 quarters · filed 2020-04-30
-9.95M GBP
derived: sum of 3 quarters · filed 2020-04-30
-17.89M GBP
20-F · filed 2020-04-30
-18.06M GBP
20-F · filed 2018-04-13
2017-10-31-10.37M GBP
derived: 6-K 9 month − 6-K 6 month · filed 2018-12-11
-780.00K GBP
derived: sum of 2 quarters · filed 2018-12-11
-8.72M GBP
6-K · filed 2018-12-11
2017-07-319.59M GBP
derived: 6-K 6 month − 6-K 3 month · filed 2018-09-20
1.65M GBP
6-K · filed 2018-09-20
2017-04-30-7.94M GBP
6-K · filed 2018-06-05
2017-01-319.14M GBP
20-F · filed 2019-03-29
2016-01-31-18.58M GBP
20-F · filed 2018-04-13

Similar stocks

Stock NameCountryMarket CapPE Ratio
BridgeBio Pharma, Inc. (BBIO)United States$12.947B-20.72
CORCEPT THERAPEUTICS INC (CORT)United States$12.804B169.10
BIOMARIN PHARMACEUTICAL INC (BMRN)United States$11.879B151.80
MADRIGAL PHARMACEUTICALS, INC. (MDGL)United States$11.859B-38.17
Elanco Animal Health Inc (ELAN)United States$11.177B-61.80
Jazz Pharmaceuticals plc (JAZZ)$15.333B16.07
Axsome Therapeutics, Inc. (AXSM)United States$10.274B-66.82
ARROWHEAD PHARMACEUTICALS, INC. (ARWR)United States$9.331B-42.28
CYTOKINETICS INC (CYTK)United States$9.130B-11.86
Protagonist Therapeutics, Inc (PTGX)United States$8.883B95.52